Skip to the main content.
DESTINY-Breast03

Breast Cancer

DESTINY-Breast03

Manufactured by: Daiichi Sankyo and AstraZeneca
Product name: ENHERTU® (trastuzumab deruxtecan/ fam-trastuzumab deruxtecan-nxki)

About the DESTINY-Breast03 Trial

The DESTINY-Breast03 trial was a Phase 3, randomized, open-label study evaluating trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer who had previously received trastuzumab and a taxane. The primary endpoint was progression-free survival (PFS), with secondary endpoints including overall survival (OS), objective response rate (ORR), and safety. T-DXd demonstrated a statistically and clinically significant improvement in PFS compared to trastuzumab emtansine (T-DM1), reinforcing its role as a superior second-line option in this setting. While the treatment was generally well tolerated, it was associated with a higher incidence of interstitial lung disease, necessitating vigilant monitoring. These results, presented at the ASCO Annual Meeting 2024, were discussed by key opinion leaders such as Dr. Yakup Ergün and Jacob Plieth, who underscored the trial's impact on evolving HER2-targeted treatment paradigms.

Table of Contents

Major Presentations and Milestones

DESTINY-Breast03 Trial design, results, and conclusions

DESTINY-Breast03 Sentiments and Criticisms

DESTINY-Breast03 Temporal Sentiment Arc

Professional Resources : Interactive Tweet History, Influence Diagram, Sentiment Table, AI Chatbot

DESTINY-Breast03 Trial: Major Presentations and Milestones

Primary speakers driving the story

Initial pivotal findings for the phase 3 DESTINY‑Breast03 trial were presented at ESMO 2021 by Javier Cortés, MD, PhD (International Breast Cancer Center, Barcelona), establishing trastuzumab deruxtecan (T‑DXd) as superior to trastuzumab emtansine (T‑DM1) in previously treated HER2‑positive metastatic breast cancer. Subsequent congress updates and journal publications have focused on durability of progression‑free survival (PFS), overall survival (OS) maturation, activity in patients with brain metastases, and interstitial lung disease (ILD) risk management. In 2024–2025 clinical discussion on social media continued to emphasize the magnitude of benefit, sequencing implications, and practical toxicity mitigation.

Representative resources and discussion:

https://www.youtube.com/watch?v=ktkJl4flG5Y

https://x.com/giammi107/status/1794242129692401674

https://x.com/dr_yakupergun/status/1794241702833926174

DESTINY-Breast03 Trial Design, Results, and Conclusions

Trial Design:

DESTINY‑Breast03 is a randomized, open‑label, phase 3 trial comparing trastuzumab deruxtecan (T‑DXd, 5.4 mg/kg IV every 3 weeks) versus trastuzumab emtansine (T‑DM1, 3.6 mg/kg IV every 3 weeks) in patients with HER2‑positive unresectable or metastatic breast cancer previously treated with trastuzumab and a taxane in the metastatic setting or who relapsed during/after adjuvant therapy. Key eligibility allowed treated and stable brain metastases. The primary endpoint was PFS by blinded independent central review (BICR); key secondary endpoints included OS, objective response rate (ORR), duration of response (DoR), and safety including adjudicated ILD/pneumonitis.

Primary Results:

T‑DXd significantly improved PFS versus T‑DM1. The hazard ratio for PFS was approximately 0.28, with median PFS reaching about 28–29 months with T‑DXd versus approximately 6–7 months with T‑DM1 in mature updates. ORR was substantially higher with T‑DXd (around 80%) compared with T‑DM1 (approximately one‑third). Updated analyses have demonstrated a statistically significant OS benefit with T‑DXd versus T‑DM1 (HR on the order of ~0.64), with median OS favoring T‑DXd. Clinically meaningful intracranial activity has been observed among patients with baseline brain metastases.

Supporting discussion links:

Safety:

The safety profile of T‑DXd requires proactive monitoring for ILD/pneumonitis, nausea/vomiting, cytopenias, and fatigue. Adjudicated ILD/pneumonitis events in DESTINY‑Breast03 occurred in a minority of patients, most commonly grade 1–2; grade ≥3 events were infrequent (<~2% in trial reports). Early recognition, treatment interruption, and corticosteroids per labeling and guidelines are central to risk mitigation. T‑DM1 toxicities included thrombocytopenia, transaminase elevations, and fatigue.

Key Conclusions:

DESTINY‑Breast03 established T‑DXd as the preferred standard after trastuzumab+taxane for HER2‑positive metastatic breast cancer, based on a large PFS advantage, higher response rates, and significant OS improvement versus T‑DM1. Intracranial activity supports use in patients with treated/stable brain metastases, with safety optimized by structured ILD surveillance and early intervention.

DESTINY-Breast03 Sentiments and Criticisms

Positive Reception:

Clinicians consistently emphasized the unprecedented magnitude of PFS benefit over T‑DM1, high ORR, and meaningful intracranial activity, reinforcing T‑DXd as the preferred option in the post‑trastuzumab+taxane setting. Representative discussions are linked for verification:

Critical Perspectives:

Constructive discussion focused on ILD risk detection and management, optimal sequencing as earlier‑line HER2 strategies evolve, and real‑world generalizability (comorbidities, prolonged treatment exposure). Representative threads:

DESTINY-Breast03 Temporal Sentiment Arc

2024 (Practice Consolidation Phase)

Primary/KOL tweets:

2025 (Refinement and Sequencing Discourse)

  • https://x.com/antgiorda/status/1979805922718523717
  • Tone: Continued focus on long‑term outcomes, sequencing across HER2‑targeted options as first‑line strategies evolve, and patient selection (brain metastases, comorbidity profiles).
  • Shift: Integration of DESTINY‑Breast03 evidence with emerging first‑line and antibody–drug conjugate data to optimize sequencing and manage overlapping toxicities.

Overall, social media discussion progressed from highlighting the magnitude of benefit to operationalizing ILD surveillance and refining sequencing strategies as datasets matured and real‑world experience accumulated.

DESTINY-Breast03 Professional Resources